Johnson & Johnson Reports 62% Lower Risk of Prostate Cancer Recurrence or Death in PROTEUS Substudy

Johnson & Johnson said Saturday that a new Phase 3 PROTEUS substudy found perioperative apalutamide plus androgen deprivation therapy reduced the risk of prostate cancer recurrence or death by 62% compared with surgery alone in patients with high-risk localized or locally advanced disease.

The result adds a new comparison that the main PROTEUS readout did not provide. Instead of comparing apalutamide plus hormone therapy with hormone therapy alone, the substudy asked how the regimen stacks up against radical prostatectomy by itself, which remains a longstanding treatment route for many patients whose cancer is still considered operable.

That distinction matters clinically because men with aggressive but non-metastatic prostate cancer often face a difficult choice between moving quickly to surgery or using more intensive therapy earlier in the hope of lowering the odds that the disease returns. Johnson & Johnson framed the new analysis as evidence that earlier use of apalutamide may improve outcomes for selected patients fit for both surgery and systemic treatment. Even so, the regimen remains investigational in this setting, and additional follow-up is still needed before the result can answer the biggest question, whether it will translate into a survival benefit.

PROTEUS substudy showed stronger event-free survival against surgery alone

The substudy enrolled 408 patients with newly diagnosed high-risk localized or locally advanced prostate cancer and compared apalutamide plus androgen deprivation therapy given for six months before and six months after surgery with immediate radical prostatectomy alone. The primary endpoint was event-free survival, a measure that counted biochemical failure, local or regional recurrence, distant metastasis or death. After a median follow-up of 37.8 months, Johnson & Johnson said the regimen cut the risk of an event or death by 62%, producing a hazard ratio of 0.38.

The time-based results give more texture to that relative-risk figure. At three years, 63% of patients who received perioperative apalutamide plus hormone therapy remained event-free, compared with 41.4% of patients who underwent surgery alone. Median event-free survival was not reached in the perioperative treatment arm, while it was 19.1 months in the surgery-alone arm, according to the company.

Secondary and exploratory endpoints moved in the same direction. Johnson & Johnson said the regimen showed a 51% lower estimated risk of metastasis or death, with a hazard ratio of 0.49. The time to first subsequent therapy also improved, with a reported 71% lower risk of needing additional treatment. At three years, 64.6% of patients in the perioperative-treatment group had not started subsequent therapy, versus 32% in the surgery-alone group. Those figures suggest the regimen may not only delay recurrence-related events but also postpone the need for another round of treatment.

Safety did not appear to produce a new signal beyond what has been reported previously for apalutamide, though the intensified regimen carried more high-grade adverse events than surgery alone. Johnson & Johnson said grade 3 or 4 treatment-emergent adverse events occurred in 31% of patients receiving apalutamide plus hormone therapy and 22% of those receiving surgery alone. No treatment-emergent adverse events leading to death were reported in either arm. Among the most common adverse events reported with apalutamide were hot flush and urinary incontinence.

Why this comparison could matter for treatment decisions

The new analysis is important partly because it addresses a limitation of the main PROTEUS study. Earlier PROTEUS results presented at ASCO 2026 compared perioperative apalutamide plus androgen deprivation therapy with placebo plus androgen deprivation therapy before and after surgery. That design showed what apalutamide added on top of hormone therapy, but it did not directly answer how the full regimen compares with surgery by itself, which remains a real-world standard option for many patients with high-risk disease.

Dana-Farber Cancer Institute, whose investigators co-led the substudy, said the new analysis helps answer that outstanding question. The institute noted that nearly half of patients with high-risk localized or locally advanced prostate cancer can see their cancer return after surgery and then require additional treatment. In that context, a direct surgery-alone comparison has more practical value for clinicians weighing whether a more intensive perioperative approach is justified.

The 62% figure also needs to be interpreted correctly. It does not mean that 62% fewer patients died during the study. The primary endpoint was event-free survival, which is broader than death alone and includes biochemical recurrence, imaging-based relapse and other disease events. That still makes the result clinically meaningful, especially in a cancer setting where recurrence can lead to more therapy, more side effects and a renewed risk of progression, but it is not the same as an overall-survival result.

The substudy results were presented as a late-breaking abstract at the European Society for Medical Oncology Congress 2026, and Dana-Farber said the accompanying manuscript has been accepted for publication in European Urology. That combination of a major-congress presentation and a journal pathway gives the findings more weight than a headline number alone, even if physicians will still want to examine the full dataset closely.

What the data mean for ERLEADA and what remains unresolved

For Johnson & Johnson, the result extends the case for using ERLEADA earlier in the prostate cancer treatment pathway. But it does not mean the drug is already cleared for this use. According to the current DailyMed prescribing information for ERLEADA, apalutamide is approved in the United States for metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer, not for high-risk localized or locally advanced disease treated before and after surgery.

That approval gap is central to how investors, clinicians and patients should read the announcement. The new substudy may support future regulatory discussions or guideline consideration, but it is not itself a label expansion. It is also worth noting that the reported metastasis-free survival result was described as a numerical or nominal improvement, and overall-survival follow-up remains ongoing. Until longer-term outcomes mature, the clearest takeaway is that the regimen appears to delay recurrence-related events and the need for subsequent therapy in a population where relapse risk remains substantial.

The question now is whether those earlier gains will prove durable enough to change routine practice. If they do, the PROTEUS program could push treatment intensification further upstream in prostate cancer care, especially for patients whose disease is still localized but biologically aggressive. For now, the next concrete milestone is additional follow-up on overall survival and fuller scrutiny of the data as the accepted manuscript becomes available to the oncology community.